Volume 17, Number 10—October 2011
CME ACTIVITY - Research
Clinical Implications of Azole Resistance in Aspergillus fumigatus, the Netherlands, 2007–2009
Table 1
Source and species | No. (%) susceptible, n = 1,978 | No. (%) resistant, n = 84 |
---|---|---|
Specimen source | ||
Sputum | 1,397 (70.6) | 64 (76.2) |
Ear swab | 176 (8.9) | 3 (3.6) |
BAL fluid | 97 (4.9) | 6 (7.1) |
Bronchus secretion | 66 (3.3) | 2 (2.4) |
Throat/nasal swab | 66 (3.3) | 1 (1.2) |
Tissue | 55 (2.8) | 5 (6.0) |
Skin swab/nail | 38 (1.9) | 1 (1.2) |
Mouth wash | 26 (1.3) | 1 (1.2) |
Pus/wound swab | 16 (0.8) | 1 (1.2) |
Bronchial wash | 11 (0.6) | 0 |
Feces | 8 (0.4) | 0 |
Unknown | 22 (1.1) | 0 |
Species | ||
A. fumigatus | 1,710 (86.5) | 82 (97.6) |
A. flavus | 98 (5.0) | 0 |
A. niger | 52 (2.6) | 2 (2.4) |
A. terreus | 35 (1.8) | 0 |
A. nidulans | 14 (0.7) | 0 |
A. versicolor | 13 (0.7) | 0 |
A. glaucus | 6 (0.3) | 0 |
Unknown | 50 (2.5) | 0
*BAL, bronchoalveolar lavage. *BAL, bronchoalveolar lavage. |
*BAL, bronchoalveolar lavage.
Page created: September 22, 2011
Page updated: September 22, 2011
Page reviewed: September 22, 2011
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.